The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimers through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company plans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.
Albert Luderer has three decades of experience in biotechnology, with a special focus on technology and business development and commercialization.
He is CEO and Board Director with personalized diagnostics company, Integrated Diagnostics.
Dr. Luderer previously served as President and CEO of BioTrove, a venture-backed molecular biological tools company that was acquired by Life Technologies.
He was also formerly CEO of venture-backed therapeutics company, Light Sciences, Inc. and President and COO of bioMrieux, Inc.
Senior management positions at Dianon Systems (Lab Corp), Boehringer Mannheim (Roche), and Corning round out Dr. Luderer’s experience in the industry.
He earned his Ph.D. from Rutgers University, where he was a National Science Foundation predoctoral fellow, and performed postgraduate work in immunology at Jefferson Medical College.
As Indis CFO, Bencich leads the companys finances and strategic company-building objectives. Prior to joining Indi, he was Allozynes chief financial officer. Earlier Bencich served as the vice president, chief financial officer and treasurer of Trubion Pharmaceuticals, a publicly traded biotechnology company, until its acquisition by Emergent BioSolutions.
Before that he was the director of finance and corporate controller for Onyx Software Corporation. Bencich started his career at Ernst & Young, the international professional services firm.
Bencich received a B.A. in accountancy from the University of San Diego and an M.B.A. from Seattle University. He received his CPA certification from Washington State and currently holds an active license.
Dr. Gregory Critchfield is CEO of Sera Prognostics, a private biotechnology company developing novel diagnostic tests for the early prediction of preterm birth and other pregnancy complications. He currently serves as an independent director of Saladax Biomedical, Metamark Genetics and Nodality. Dr. Critchfield is also past President of Myriad Genetic Laboratories, Inc., where he successfully established the companys medical, scientific, and commercial capabilities beginning in 1998 until he retired in March 2010.
During this time, Dr. Critchfield built Myriad Genetic Laboratories into one of the worlds leading molecular diagnostics companies, launching seven novel diagnostics products across multiple technology platforms and growing annual revenues from $2.2 million to $326.5 million.
In the spin-out of Quest Diagnostics, Inc. from Corning Clinical Laboratories, Dr. Critchfield was responsible for innovation and medicine, serving as Quests Chief Medical and Science Officer.
Lee Hood, M.D., Ph.D., is an unparalleled pioneer in the translation of technology from R&D to industry. He has co-founded more than 14 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. Amgen and Applied Biosystems have a combined market capitalization of over $50B.
Dr. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Academy of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. He is one of only 10 members out of more than 6000 that are in all three US National Academies (NAS, IOM, and NAE).
In 2012 Dr. Hood received the National Medal of Science, the highest honor awarded scientists by the United States government. He is also the 2011 recipient of the Russ Prize, awarded by the National Academy of Engineering, for his development of the automated DNA sequencera tool that has revolutionized biomedicine and forensic science.
Dr. Jim Heath is Gilloon Professor and Professor of Chemistry at the California Institute of Technology. He received a B.Sc. degree in chemistry from Baylor University in 1984, and a Ph.D. degree in chemistry from Rice University in 1988, where he studied in the group of Richard E. Smalley.
Dr. Heath was a Miller Postdoctoral Fellow at UC Berkeley from 1988 to 1991, and a research staff member at the IBM T.J. Watson Research Labs in Yorktown Heights, New York from 1991 to 1994. In 1994 he left IBM to join the Department of Chemistry and Biochemistry at UCLA. He was the founding director of the California NanoSystems Institute (CNSI), prior to moving to Caltech in 2003.
Dr. Heath is a Fellow of the American Physical Society, and his awards include Jules Springer Award in Applied Physics (2000); the Feynman Prize (2000); the Sackler Prize in the Physical Sciences (2001), and the Spiers Medal from the Royal Society (2005). Dr.
Jay Moyes is a well-known life sciences entrepreneur with an extensive track record of success in molecular diagnostics. He is the past chief financial officer of Myriad Genetics where he led all accounting, HR and IT efforts.
During his 14 years at Myriad, Moyes developed and maintained relationships with key bankers, analysts and investors, raising more than $500 million in public and private equity. He played a key role in growing the company from a startup into one of the worlds top molecular diagnostics companies, with annual revenue in excess of $300 million.
While at Myriad, Moyes collaborated closely with fellow Indi Board member, Gregory Critchfield, M.D., M.S., who served as CEO of Myriads diagnostic laboratory for nearly 12 years. After his tenure at Myriad, Moyes held the position of CFO at XDx, an emerging molecular diagnostics company where he was a collegue of Kenneth C. Fang, M.D, who now serves as Indi’s chief medical officer.
David L. Barker was Vice President and Chief Scientific Officer at Illumina, Inc., in San Diego, California from 2000 through 2006.
Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric.
From 1988 to 1998, he held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until their acquisition by Amersham.
He currently serves on the Boards of Cell Biosciences, Integrated Diagnostics, IntegenX Inc., and NextBio, and is a scientific advisor to Illumina, GenVault, Diagnostics for the Real World, BiOptix, and DNA Direct.
In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University.
Dr. Barker holds a B.S.
Dr. Arnie Oronsky has been with InterWest’s life sciences team since 1994.
He is a board member of Amplimmune, Applied Genetic Technologies Corporation (AGTC), Arcion, Drais Pharmaceuticals, Dynavax Technologies (DVAX), Integrated Diagnostics, MacroGenics, RadioRX, TESARO and USDS.
As a Ph.D. in immunology and senior lecturer at the Department of Medicine at Johns Hopkins Medical School, Arnie brings a deep understanding of medical research to finding and investing in successful life sciences companies.
Prior to joining InterWest, Arnie was vice president for discovery research of the Lederle Laboratories division of American Cyanamid Company where he directed the research for new drugs.
Arnie received a Ph.D. in immunology from Columbia University and has published more than 125 articles in scientific journals.
Dr. David Galas is Principal Scientist at Pacific Northwest Diabetes Research Institute, formerly holding the positions of Professor and Senior Vice President at the Institute for Systems Biology. Prior to that, he was Chief Science Officer for Life Sciences of the Battelle Memorial Institute. He was previously Chancellor, Chief Scientific Officer and Norris Professor of Applied Life Science at the Keck Graduate Institute of Applied Life Sciences (KGI), in Claremont, Calif., a research and educational institution in the applied life sciences, which he co-founded. Earlier, Dr. Galas served as President and Chief Scientific Officer of Seattle-based Chiroscience R&D, Inc., a genomics and drug discovery company formed through the acquisition of Darwin Molecular Corporation, which Dr. Galas co-founded in 1993 and served as CEO and Chief Scientific Officer.
Dr. Galas has also served as Director for Health and Environmental Research at the U.S.
As Indis Chief Business Officer, James Jim Garner leads the companys commercialization efforts including global marketing, sales, customer support and commercial partner agreements.
Garner brings 25 years of experience as a sales and marketing executive much of it spent selling complex, multi-million dollar data products and technical services to chief executives of life sciences and health insurance companies. His background includes building, developing, and leading high performance sales and customer support teams.
Prior to his appointment as CBO, Garner served as a consultant to Indi for more than a year. Previously he worked at UnitedHealth Group, most recently as senior vice president, global sales, i3 Research.
Earlier in his career he was vice president, sales at MDdatacor, a medical informatics company and as director of marketing for Elan Diagnostics.
Paul Kearney, Ph.D., joined the Institute for Systems Biology in 2008 as Scientific Director of Special Projects where he helped establish a $100M collaboration in Personalized Medicine between ISB and the University of Luxembourg.
Previously, Dr. Kearney was VP Bioinformatics at Caprion Proteomics, a leading provider of proteomics services for biomarker discovery. At Caprion he managed technology R&D, oversaw all aspects of data analysis, IT and biomarker panel discovery and experimental design.
Prior to Caprion, Dr. Kearney was co-founder and VP R&D of Bioinformatics Solutions (BSI), a provider of genomic and proteomic data analysis tools. BSI won an R&D 100 award and the CASP4 competition for its PROSPECT tool for automated protein structure prediction.
Prior to BSI, Dr. Kearney was assistant professor of Computer Science at the University of Waterloo where he was the founder and inaugural Director of the Bioinformatics Program.